Executive Summary
Publicis Groupe S.A. gains bullish exposure via subsidiary Plowshare Group's $373.9M HHS/CDC contract (up to $497.8M with options), with $275.5M (74%) already outlayed, affirming multi-year stable revenue in advertising. Near contract end (2026-03-30), $123.9M unexercised options present immediate upside. Monitor disbursements and renewals amid audit and funding risks.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior Contract Option Exercises digest from March 29, 2026.
Investment Signals (1)
- Stable $374M CDC Revenue Stream for Publicis (HIGH)▲
$373.9M obligated (potential $497.8M), $275.5M outlayed under Time & Materials contract bolsters Publicis Groupe S.A. financials through 2026.
Risk Flags (2)
- Execution [MEDIUM RISK]▼
Time & Materials structure risks audits on hours/rates; $98.4M (26%) of obligated funds remain undisbursed.
- Regulatory [MEDIUM RISK]▼
Contract end 2026-03-30 exposes to funding cuts or non-renewal uncertainty.
Opportunities (2)
- ◆
$123.9M unexercised options available for activation.
- ◆
Follow-on CDC tobacco campaign work post-2026.
Sector Themes (1)
- ◆
$374M CDC award highlights sustained federal spend on tobacco education via NAICS 541810 agencies.
Watch List (2)
- 👁
{"entity"=>"Publicis Groupe S.A.", "reason"=>"Resolution of $374M contract at 2026-03-30 with $124M options.", "trigger"=>"Exercises, closeouts, or Q1 2026 earnings guidance"}
- 👁
{"entity"=>"CDC Tobacco Campaign Budget", "reason"=>"Drives potential renewals in $500M-scale public health advertising.", "trigger"=>"FY2027 HHS appropriations or new awards"}
Get daily alerts with 1 investment signals, 2 risk alerts, 2 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: Contract Option Exercises
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals